Edgestream Partners, L.P.

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1535061 Princeton, NJ

Position in ACAD

as of Mar 31, 2026 · filed May 18, 2026 Compact

Position Value

$4,258,961

-$4,187,782 QoQ

Shares Held

191,328

-39.5% QoQ

Ownership

0.112%

of shares outstanding

% of Portfolio

0.15%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

12 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Edgestream Partners, L.P. holds $88,282,973 across 25 Biotechnology names. ACAD ranks #8 (4.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INCY	Incyte Corp	157,472	$14,821,264
2	EXEL	Exelixis, Inc.	174,455	$7,482,374
3	RVMD	Revolution Medicines, Inc.	69,262	$6,735,729
4	ARWR	Arrowhead Pharmaceuticals, Inc.	91,997	$5,768,211
5	TGTX	Tg Therapeutics, Inc.	168,351	$5,592,620
6	IONS	Ionis Pharmaceuticals Inc	68,369	$5,133,828
7	AGIO	Agios Pharmaceuticals, Inc.	143,731	$4,862,419
8	ACAD	Acadia Pharmaceuticals Inc This page	191,328	$4,258,961

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$4,258,961	191,328	-39.5%	Shares	Sole	2026-05-18
2025-12-31	$8,446,743	316,239	+35.2%	Shares	Sole	2026-02-13
2025-09-30	$4,990,252	233,845	+110.4%	Shares	Sole	2025-11-12
2025-06-30	$2,397,376	111,144	-30.1%	Shares	Sole	2025-08-13
2025-03-31	$2,642,783	159,108	-39.8%	Shares	Sole	2025-05-02
2024-12-31	$4,851,556	264,390	+20.5%	Shares	Sole	2025-02-07
2024-09-30	$3,373,280	219,329	+141.1%	Shares	Sole	2024-11-14
2024-06-30	$1,478,051	90,957	+46.9%	Shares	Sole	2024-08-09
2024-03-31	$1,144,641	61,906	+63.3%	Shares	Sole	2024-05-10
2023-12-31	$1,186,899	37,908	+290.7%	Shares	Sole	2024-02-14
2023-09-30	$202,210	9,703	-88.5%	Shares	Sole	2023-11-15
2023-06-30	$2,015,871	84,170	—	Shares	Sole	2023-08-10
No filing history on record for this holder in this stock.